Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Early Defense: Answering Key Questions About the Science and Strategy of RSV Prevention in Infants
Test, Treat, Repeat: Closing Persistent Gaps in HCV Care
When Form Maximizes Function: Examining the Role of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice
Precision Use of Biologic Therapies in Eosinophilic Lung Disease: Case-Based Strategies to Optimize Treatment Selection and Reduce Steroid Burden
Free AI-powered recaps of CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.